Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of D-Glutamate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D known ✓ | O15399 | 1/20 | 0.75 |
| ▸ | GRIN3B known ✓ | O60391 | 1/20 | 0.75 |
| ▸ | GRIN1 known ✓ | Q05586 | 1/20 | 0.75 |
| ▸ | GRIN2A known ✓ | Q12879 | 1/20 | 0.75 |
| ▸ | GRIN2B known ✓ | Q13224 | 1/20 | 0.75 |
| ▸ | GRIN2C known ✓ | Q14957 | 1/20 | 0.75 |
| ▸ | GRIN3A known ✓ | Q8TCU5 | 1/20 | 0.75 |
| ▸ | GRM8 | O00222 | 2/20 | 0.75 |
| ▸ | GRM6 | O15303 | 2/20 | 0.75 |
| ▸ | GRM7 | Q14831 | 2/20 | 0.75 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.75 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.75 |
| ▸ | GSR | P00390 | 1/20 | 0.75 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.75 |
| ▸ | GRM5 | P41594 | 1/20 | 0.75 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.75 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.75 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.75 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.75 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glutamic Acid SCHEMBL5017170 | 1.00 | GRM8 (0.75) | GRM8GRM6GRM7GRM4CYP1A2 | |
| Glutamic Acid SCHEMBL1667361 | 0.91 | GRM8 (0.82) | GRM8GRM6GRM7GRM4CYP1A2 | |
| D-Glutamate SCHEMBL28742738 | 0.91 | GRM8 (0.82) | GRM8GRM6GRM7GRM4CYP1A2 | |
| D-Glutamate SCHEMBL1667360 | 0.91 | GRM8 (0.82) | GRM8GRM6GRM7GRM4CYP1A2 | |
| D-Glutamate SCHEMBL29060279 | 0.90 | GRM8 (0.72) | GRM8GRM6GRM7GRM4CYP1A2 | |
| Glutamic Acid SCHEMBL29259695 | 0.89 | GRM8 (0.78) | GRM8GRM6GRM7GRM4CYP1A2 | |
| D-Glutamate SCHEMBL29259696 | 0.89 | GRM8 (0.78) | GRM8GRM6GRM7GRM4CYP1A2 | |
| Glutamic Acid SCHEMBL5692202 | 0.89 | GRM8 (0.78) | GRM8GRM6GRM7GRM4CYP1A2 | |
| Glutamic Acid SCHEMBL28070258 | 0.89 | GRM8 (0.78) | GRM8GRM6GRM7GRM4CYP1A2 | |
| D-Glutamate SCHEMBL5691701 | 0.89 | GRM8 (0.78) | GRM8GRM6GRM7GRM4CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7078564-B2 | Process for the preparation of ωbenzyl esters of amino diacids and of alkanesulphonates of these esters, and these alkanesulphonates | ISOCHEM (FR) | 2006-07-18 | — | — | US | claimed |
| US-20040133033-A1 | Process for the preparation of omega-benzyl esters of amino diacids and of alkanesulphonates of these esters, and these alkanesulphonates | ISOCHEM (FR) | 2004-07-08 | — | — | US | claimed |
| CN-115093902-A | Method for preparing biodiesel by catalyzing amino acid methane sulfonate ionic liquid | 昆明理工大学 | 2022-09-23 | — | — | CN | disclosed |
| CN-110023315-A | Novel compound or pharmacologically acceptable salt thereof | 国立研究开发法人理化学研究所 | 2019-07-16 | — | — | CN | disclosed |
| US-20180256717-A1 | PROTEIN COMPOSITIONS AND USE THEREOF | DRUG DISCOVERY LABORATORY AS (NO) | 2018-09-13 | — | — | US | disclosed |
| EP-3236942-A1 | PROTEIN COMPOSITIONS AND USE THEREOF | Drug Discovery Laboratory AS (NO) | 2017-11-01 | — | — | EP | disclosed |
| WO-2016103034-A1 | PROTEIN COMPOSITIONS AND USE THEREOF | DRUG DISCOVERY LABORATORY AS (NO) | 2016-06-30 | — | — | WO | disclosed |
| CN-101507820-A | Manufacture of polyglutamate-therapeutic agent conjugates | CELL THERAPEUTICS INC (US) | 2009-08-19 | — | — | CN | disclosed |
| US-7399860-B2 | Manufacture of polyglutamate-therapeutic agent conjugates | CELL THERAPEUTICS INC. (US) | 2008-07-15 | — | — | US | disclosed |
| US-7078564-B2 | Process for the preparation of ωbenzyl esters of amino diacids and of alkanesulphonates of these esters, and these alkanesulphonates | ISOCHEM (FR) | 2006-07-18 | — | — | US | disclosed |
| CN-1607962-A | Method for producing polyglutamic acid-therapeutic agent conjugates | CELL THERAPEUTICS INC (US) | 2005-04-20 | — | — | CN | disclosed |
| EP-1466627-A1 | Polyglutamate camptothecin conjugates | CELL THERAPEUTICS, INC. (US) | 2004-10-13 | — | — | EP | disclosed |
| EP-1439166-A1 | Process for the preparation of omega-benzyl ester of amino diacids and its alcanesulfonates and the alcanesulfonates itself | ISOCHEM (FR) | 2004-07-21 | — | — | EP | disclosed |
| US-20040133033-A1 | Process for the preparation of omega-benzyl esters of amino diacids and of alkanesulphonates of these esters, and these alkanesulphonates | ISOCHEM (FR) | 2004-07-08 | — | — | US | disclosed |
| US-20030224971-A1 | Manufacture of polyglutamate-therapeutic agent conjugates | CELL THERAPEUTICS, INC. | 2003-12-04 | — | — | US | disclosed |
| EP-0952157-B1 | 9A, 11B-Dehydro derivatives of 9-oxime-3-keto-6-0-methylerythromycin | PFIZER PROD INC (US) | 2003-06-18 | — | — | EP | disclosed |
| US-20030054977-A1 | Manufacture of polyglutamate-therapeutic agent conjugates | CELL THERAPEUTICS, INC. | 2003-03-20 | — | — | US | disclosed |
| EP-1225917-A2 | MANUFACTURE OF POLYGLUTAMATE-THERAPEUTIC AGENT CONJUGATES | CELL THERAPEUTICS, INC. (US) | 2002-07-31 | — | — | EP | disclosed |
| US-20020077279-A1 | Manufacture of polyglutamate-therapeutic agent conjugates | KUMAR ANIL M (US) | 2002-06-20 | — | — | US | disclosed |
| WO-2001026693-A2 | MANUFACTURE OF POLYGLUTAMATE-THERAPEUTIC AGENT CONJUGATES | CELL THERAPEUTICS, INC. (US) | 2001-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040133033-A1 | Process for the preparation of omega-benzyl esters of amino diacids and of alkanesulphonates of these esters, and these alkanesulphonates | ADH1C, DRD1, ABHD6 | GRIN2D 636/4885GRIN3B 3393/4885GRIN1 1623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.